ID: ALA2297887

Max Phase: Preclinical

Molecular Formula: C16H33Br3N4S

Molecular Weight: 310.51

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Br.Br.Br.CCCN(C)CCc1csc(N2CCN(CCC)CC2)n1

Standard InChI:  InChI=1S/C16H30N4S.3BrH/c1-4-7-18(3)9-6-15-14-21-16(17-15)20-12-10-19(8-5-2)11-13-20;;;/h14H,4-13H2,1-3H3;3*1H

Standard InChI Key:  HSNWWHPXCRXKQR-UHFFFAOYSA-N

Associated Targets(non-human)

Histamine H3 receptor 1015 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 310.51Molecular Weight (Monoisotopic): 310.2191AlogP: 2.56#Rotatable Bonds: 8
Polar Surface Area: 22.61Molecular Species: BASEHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 9.13CX LogP: 3.29CX LogD: 1.07
Aromatic Rings: 1Heavy Atoms: 21QED Weighted: 0.74Np Likeness Score: -2.38

References

1. Guryn R, Staszewski M, Walczyński K..  (2013)  Non-imidazole histamine H3 ligands: part V. synthesis and preliminary pharmacological investigation of 1-[2-thiazol-4-yl- and 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives.,  22  (8): [PMID:23807824] [10.1007/s00044-012-0372-8]

Source